On September 8, Bristol-Myers Squibb fell 3.05% in regular trading, trading at $64.585/share, with turnover of approximately $43.82 million.

On the news front, the company announced that its potentially first-in-class GPRC5D-targeted CAR-T cell therapy, Arlocabtagene Autoleucel, met the primary and key secondary endpoints of a pivotal Phase 2 trial (QUINTESSENTIAL) for adults with quadruple-class exposed relapsed and refractory multiple myeloma. The study demonstrated a statistically significant overall response rate in heavily pretreated patients with at least four prior lines of therapy, and a complete response rate in patients with at least three prior lines.

However, the positive data failed to lift the stock as broader CAR-T safety headwinds weighed heavily on the pharma sector. Novartis plunged 12.57% after halting eight CAR-T clinical trials following three patient deaths linked to severe immune reactions. Bristol-Myers Squibb itself had previously paused enrollment in its Zola-cel autoimmune disease trials over inflammatory side effects. The sector-wide selloff — with Johnson & Johnson down 2.77%, Eli Lilly down 2.36%, and Pfizer down 2.21% — overshadowed company-specific catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)